Academic Radiology
Volume 14, Issue 5 , Pages 561-573 , May 2007

Monitoring Breast Cancer Response to Neoadjuvant Systemic Chemotherapy Using Parametric Contrast-Enhanced MRI: A Pilot Study

  • Chen-Pin Chou, MD

      Affiliations

    • Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    • School of Medicine, National Yang Ming University, Taipei, Taiwan, ROC
    • ,
  • Ming-Ting Wu, MD

      Affiliations

    • Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    • School of Medicine, National Yang Ming University, Taipei, Taiwan, ROC
    • ,
  • Hong-Tai Chang, MD

      Affiliations

    • Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    • School of Medicine, National Yang Ming University, Taipei, Taiwan, ROC
    • ,
  • Yu-Shin Lo, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    • School of Medicine, National Yang Ming University, Taipei, Taiwan, ROC
    • ,
  • Huay-Ben Pan, MD

      Affiliations

    • Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    • School of Medicine, National Yang Ming University, Taipei, Taiwan, ROC
    • ,
  • Hadassa Degani, PhD

      Affiliations

    • Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
    • ,
  • Edna Furman-Haran, PhD

      Affiliations

    • Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
    • Corresponding Author InformationAddress correspondence to: E.F.H.

Received 27 January 2007 ,Accepted 7 February 2007.

References 

  1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–1949
  2. Helbich TH. Contrast-enhanced magnetic resonance imaging of the breast. Eur J Radiol. 2000;34:208–219
  3. Padhani AR, Ah-See ML, Makris A. MRI in the detection and management of breast cancer. Expert Rev Anticancer Ther. 2005;5:239–252
  4. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology. 1989;170:681–686
  5. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther. 2003;2:419–426
  6. Schnall MD, Blume J, Bluemke DA, et al. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006;238:42–53
  7. Rieber A, Brambs HJ, Gabelmann A, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002;12:1711–1719
  8. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13:1213–1223
  9. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001;8:549–559
  10. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat. 2003;78:51–58
  11. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2003;181:1275–1282
  12. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83:67–76
  13. El Khoury C, Servois V, Thibault F, et al. MR quantification of the washout changes in breast tumors under preoperative chemotherapy: feasibility and preliminary results. AJR Am J Roentgenol. 2005;184:1499–1504
  14. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179:1193–1199
  15. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005;184:1774–1781
  16. Delille JP, Slanetz PJ, Yeh ED, et al. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology. 2003;228:63–69
  17. Chang YC, Huang CS, Liu YJ, et al. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol. 2004;49:3593–3602
  18. Armitage P, Behrenbruch C, Brady M, et al. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal. 2005;9:315–329
  19. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006;239:361–374
  20. Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91:1–10
  21. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002;15:154–163
  22. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006;94:427–435
  23. Fischer U, Zachariae O, Baum F, et al. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol. 2004;14:1725–1731
  24. Thibault F, Nos C, Meunier M, et al. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. AJR Am J Roentgenol. 2004;183:1159–1168
  25. Denis F, Desbiez-Bourcier AV, Chapiron C, et al. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol. 2004;30:1069–1076
  26. Degani H, Gusis V, Weinstein D, et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med. 1997;3:780–782
  27. Furman-Haran E, Degani H. Parametric analysis of breast MRI. J Comput Assist Tomogr. 2002;26:376–386
  28. Kelcz F, Furman-Haran E, Grobgeld D, et al. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol. 2002;179:1485–1492
  29. Furman-Haran E, Grobgeld D, Margalit R, et al. Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method. Clin Cancer Res. 1998;4:2299–2304
  30. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357–367
  31. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91–101
  32. Furman-Haran E, Schechtman E, Kelcz F, et al. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer. 2005;104:708–718
  33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  34. Moneer M, El-Didi M, Khaled H. Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy? A pathological assessment. Breast. 1999;8:315–319
  35. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37–47quiz 50–31
  36. Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference. Cancer. 1999;86:2436–2446
  37. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  38. Yankeelov TE, Rooney WD, Li X, et al. Variation of the relaxographic “shutter-speed” for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med. 2003;50:1151–1169
  39. Dadiani M, Margalit R, Sela N, et al. High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. Cancer Res. 2004;64:3155–3161
  40. Hassid Y, Furman-Haran E, Margalit R, et al. Non invasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res. 2006;66:4159

1 Supported by a research grant from Kaohsiung Veterans General Hospital, VGHKS-91–84, an Israel Science Foundation grant (number 801/04) and by Lord David Alliance, United Kingdom.

PII: S1076-6332(07)00092-X

doi: 10.1016/j.acra.2007.02.005

Academic Radiology
Volume 14, Issue 5 , Pages 561-573 , May 2007

Article Tools

* Image Usage & Resolution